Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer.

Hdl Handle:
http://hdl.handle.net/10147/141058
Title:
Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer.
Authors:
Baird, Anne-Marie; Gray, Steven G; O'Byrne, Kenneth J
Affiliation:
Thoracic Oncology Research Group, Institute of Molecular Medicine, Trinity College, Dublin, Ireland.
Citation:
Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. 2011, 6 (1):e14593 PLoS ONE
Journal:
PloS one
Issue Date:
Jan-2011
URI:
http://hdl.handle.net/10147/141058
DOI:
10.1371/journal.pone.0014593
PubMed ID:
21298036
Abstract:
Angiogenesis may play a role in the pathogenesis of Non-Small Cell Lung cancer (NSCLC). The CXC (ELR(+)) chemokine family are powerful promoters of the angiogenic response.; The expression of the CXC (ELR(+)) family members (CXCL1-3/GROα-γ, CXCL8/IL-8, CXCR1/2) was examined in a series of resected fresh frozen NSCLC tumours. Additionally, the expression and epigenetic regulation of these chemokines was examined in normal bronchial epithelial and NSCLC cell lines.; Overall, expression of the chemokine ligands (CXCL1, 2, 8) and their receptors (CXCR1/2) were down regulated in tumour samples compared with normal, with the exception of CXCL3. CXCL8 and CXCR1/2 were found to be epigenetically regulated by histone post-translational modifications. Recombinant CXCL8 did not stimulate cell growth in either a normal bronchial epithelial or a squamous carcinoma cell line (SKMES-1). However, an increase was observed at 72 hours post treatment in an adenocarcinoma cell line.; CXC (ELR(+)) chemokines are dysregulated in NSCLC. The balance of these chemokines may be critical in the tumour microenvironment and requires further elucidation. It remains to be seen if epigenetic targeting of these pathways is a viable therapeutic option in lung cancer treatment.
Item Type:
Article
Language:
en
MeSH:
Biopsy; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Chemokine CXCL1; Chemokine CXCL2; Chemokines, CXC; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Lung Neoplasms; Neovascularization, Pathologic; Protein Processing, Post-Translational; Receptors, Interleukin-8A; Receptors, Interleukin-8B
ISSN:
1932-6203

Full metadata record

DC FieldValue Language
dc.contributor.authorBaird, Anne-Marieen
dc.contributor.authorGray, Steven Gen
dc.contributor.authorO'Byrne, Kenneth Jen
dc.date.accessioned2011-08-29T10:08:28Z-
dc.date.available2011-08-29T10:08:28Z-
dc.date.issued2011-01-
dc.identifier.citationEpigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. 2011, 6 (1):e14593 PLoS ONEen
dc.identifier.issn1932-6203-
dc.identifier.pmid21298036-
dc.identifier.doi10.1371/journal.pone.0014593-
dc.identifier.urihttp://hdl.handle.net/10147/141058-
dc.description.abstractAngiogenesis may play a role in the pathogenesis of Non-Small Cell Lung cancer (NSCLC). The CXC (ELR(+)) chemokine family are powerful promoters of the angiogenic response.-
dc.description.abstractThe expression of the CXC (ELR(+)) family members (CXCL1-3/GROα-γ, CXCL8/IL-8, CXCR1/2) was examined in a series of resected fresh frozen NSCLC tumours. Additionally, the expression and epigenetic regulation of these chemokines was examined in normal bronchial epithelial and NSCLC cell lines.-
dc.description.abstractOverall, expression of the chemokine ligands (CXCL1, 2, 8) and their receptors (CXCR1/2) were down regulated in tumour samples compared with normal, with the exception of CXCL3. CXCL8 and CXCR1/2 were found to be epigenetically regulated by histone post-translational modifications. Recombinant CXCL8 did not stimulate cell growth in either a normal bronchial epithelial or a squamous carcinoma cell line (SKMES-1). However, an increase was observed at 72 hours post treatment in an adenocarcinoma cell line.-
dc.description.abstractCXC (ELR(+)) chemokines are dysregulated in NSCLC. The balance of these chemokines may be critical in the tumour microenvironment and requires further elucidation. It remains to be seen if epigenetic targeting of these pathways is a viable therapeutic option in lung cancer treatment.-
dc.language.isoenen
dc.subject.meshBiopsy-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCell Line-
dc.subject.meshCell Line, Tumor-
dc.subject.meshChemokine CXCL1-
dc.subject.meshChemokine CXCL2-
dc.subject.meshChemokines, CXC-
dc.subject.meshEpigenesis, Genetic-
dc.subject.meshGene Expression Regulation, Neoplastic-
dc.subject.meshHumans-
dc.subject.meshInterleukin-8-
dc.subject.meshLung Neoplasms-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshProtein Processing, Post-Translational-
dc.subject.meshReceptors, Interleukin-8A-
dc.subject.meshReceptors, Interleukin-8B-
dc.titleEpigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentThoracic Oncology Research Group, Institute of Molecular Medicine, Trinity College, Dublin, Ireland.en
dc.identifier.journalPloS oneen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.